Pi3k/Akt Pathway Biomarkers Analysis From The Phase Iii Ipatential150 Trial Of Ipatasertib Plus Abiraterone In Metastatic Castration-Resistant Prostate Cancer.

Johann S. De Bono,Christopher Sweeney,Sergio Bracarda,Cora N. Sternberg,Kim N. Chi,David Olmos,Shahneen Kaur Sandhu,Christophe Massard,Nobuaki Matsubara,Josep Garcia,Malgorzata Nowicka,Matthew Wongchenko,Zhen Shi

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 17|浏览22

暂无评分

摘要

13Background: In IPATential150 (NCT03072238), ipatasertib (ipat) + abiraterone (abi) as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly reduced the ri...

查看译文

关键词

Prostate cancer,Ipatasertib,PI3K/AKT/mTOR pathway,Oncology,Biomarker (medicine),Medicine,Abiraterone,Castration resistant,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要